Spring Bank Pharmaceuticals Inc

Spring Bank Pharmaceuticals — Corporate Update (August 2018)

19 slides from Spring Bank Pharmaceuticals's corporate update, Aug 2, 2018

  1. Slide 1: Inarigivir ACHIEVE Trial Results and HBV Clinical Program Update

    Inarigivir ACHIEVE Trial Results and HBV Clinical Program Update August 2, 2018 Exhibit 99.1

  2. Slide 2: Forward-looking statements

    This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among other things, statements, other than historical facts, regarding: the progress, scope, duration or results of clinical trials an

  3. Slide 3: Inarigivir ACHIEVE Trial Results and HBV Clinical Program Update

    1 • SPRING BANK PHARMACEUTICALS INC. © 2018 Dose dependent responses in Cohort 3 in the ongoing ACHIEVE Trial Best HBsAg responder rate (28%) for oral therapies in HBV development space Gilead has expanded the inarigivir + Vemlidy® collaboration with Spring Bank Expanding and accelerating the clinic

  4. Slide 4: Inarigivir: A Novel, Oral Selective Immunomodulator with a Dual Mechanism of Action

    2 • SPRING BANK PHARMACEUTICALS INC. © 2018 INARIGIVIR: A NOVEL, ORAL SELECTIVE IMMUNOMODULATOR WITH A DUAL MECHANISM OF ACTION HBV, hepatitis B virus; IFN, interferon; pgRNA, pregenomic RNA; RIG-I, retinoic acid-inducible gene-I. Sato et al. Immunity. 2015;42:123-132. INARIGIVIR is a RIG–I AGONIST

  5. Slide 5: Inarigivir MOA Studies Indicate Key Role for Selective Hepatic Immuno-modulation

    PRE-CLINICAL DATA Inarigivir binds to CARDs and regulatory domain of RIG-I with activation of IRF-3 and hepato-selective innate immune response Inarigivir up-regulates intra-hepatic RIG-I, activates intra-hepatic ISGs and suppresses HBsAg, HBV DNA, HBV RNA and cccDNA in the woodchuck model CLINICAL

  6. Slide 6: Clinical Studies of Inarigivir in HBV

    4 • SPRING BANK PHARMACEUTICALS, INC. © 2018 CLINICAL STUDIES OF INARIGIVIR IN HBV DNA, deoxyribonucleic acid; HBeAg, hepatitis B e antigen; RNA, ribonucleic acid; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; QD, once daily. PRIMARY ENDPOINT SECONDARY ENDPOINT Safety and antiviral act

  7. Slide 7: ACHIEVE Study Baseline Demographics

    Placebo 25 mg HBeAg +ve 25 mg HBeAg -ve 50 mg HBeAg +ve 50 mg HBeAg -ve 100 mg HBeAg +ve 100 mg HBeAg -ve Number 11 9 7 11 5 13 4 Mean Age 40 37 43 36 47 34 46 Gender M:F 7:4 5:5 3:3 9:2 5:0 7:6 3:1 Mean Baseline ALT 69 82 75 75 65 75 90 Mean Baseline HBV DNA log10 6.20 7.86 5.69 7.79 4.55 8.20 5.95

  8. Slide 8: Inarigivir Demonstrates a Continuing Positive Dose Response in HBeAg +ve Patients at Week 12

    6 • SPRING BANK PHARMACEUTICALS, INC. © 2018 HBV DNA 1 0 -1 -2 Placebo 25 mg 50 mg 100 mg Placebo 25 mg 50 mg 100 mg HBV RNA 0.5 0.0 -1.0 -1.5 -0.5 -2.0 Inarigivir 100 mg vs PL *p<0.05 * # Inarigivir vs PL *p<0.03 #p<0.02 Inarigivir Inarigivir Log10 Decline HBV DNA Log10 Decline HBV RNA Inarigivir D

  9. Slide 9: Inarigivir Demonstrates a Continuing Positive Dose Response in HBeAg -ve Patients at Week 12

    7 • SPRING BANK PHARMACEUTICALS, INC. © 2018 INARIGIVIR DEMONSTRATES A CONTINUING POSITIVE DOSE RESPONSE IN HBeAg -VE PATIENTS AT WEEK 12 HBV DNA HBV RNA Placebo 25 mg 50 mg and 100 mg 4 2 -2 -4 0 -6 2 1 -1 -2 0 -3 Placebo 25 mg 50 mg 100 mg All groups p<0.01 All groups p<0.01 5 patients undetectabl

  10. Slide 10: In All Cohorts: Baseline HBsAg Predicts Response of Both DNA and RNA to Inarigivir

    Patients: HBsAg <4 log: 16 HBeAg –ve, 10 HBeAg +ve 8 • SPRING BANK PHARMACEUTICALS, INC. © 2018 IN ALL COHORTS: BASELINE HBsAg PREDICTS RESPONSE OF BOTH DNA AND RNA TO INARIGIVIR 1 -1 -2 0 -3 Subjects with Baseline HBsAg >4 log Subjects with Baseline HBsAg <4 log HBV DNA p<0.001 Subjects with Baseli

  11. Slide 11: Summary of ACHIEVE Phase 2 Data from Cohorts 1, 2 and 3 on HBsAg

    9 • SPRING BANK PHARMACEUTICALS, INC. © 2018 SUMMARY OF ACHIEVE PHASE 2 DATA FROM COHORTS 1,2 and 3 ON HBsAg Only oral drug to demonstrate meaningful clinical effect on HBsAg Overall, 13 of 47 (28%) patients experienced a 0.5 log10 reduction on inarigivir alone or at 24 weeks after TDF switch Mean H

  12. Slide 12: Effect of Oral Approved or Investigational HBV Drugs on HBsAg

    10 • SPRING BANK PHARMACEUTICALS, INC. © 2018 EFFECT OF ORAL APPROVED OR INVESTIGATIONAL HBV DRUGS ON HBsAg TLR-7 (Vesatolimod 4 mg) Week 12 mean reduction: 0.05 log10 No patient >0.5 log10 reduction No effect reported on HBsAg at week 4 TDF / TAF Week 48 mean reduction: HBeAg +ve 0.3 log10 HBeAg –v

  13. Slide 13: Global HBV Clinical Collaboration with Gilead

    Vemlidy® monotherapy Inarigivir - 50 mg + Vemlidy® Inarigivir - 200 mg + Vemlidy® GLOBAL HBV CLINICAL COLLABORATION WITH GILEAD Inarigivir co-administered with Vemlidy® (tenofovir alafenamide) 25 mg in naïve patients Expanded Gilead Phase 2 HBV Study Vemlidy® 12 weeks 36 weeks Initiated by Gilead in

  14. Slide 14: Inarigivir Development Plan Accounts for HBV Heterogeneity

    70-80% of chronic HBV patients Dominant population in US & EU Older age group Lower viral burden SB 9225 + siRNA SB 9225 + different MOA or “Stop & Shock” Inarigivir monotherapy “Suppress & Shock” Inarigivir + existing OAV INARIGIVIR DEVELOPMENT PLAN ACCOUNTS FOR HBV HETEROGENEITY Naïve or new to tr

  15. Slide 15: "Stop & Shock" – Inarigivir Monotherapy

    S 13 • SPRING BANK PHARMACEUTICALS, INC. © 2018 “SHOCK” inarigivir once daily for 12-24 weeks Virally suppressed patients stop NUC treatment 10-20% OF PATIENTS Host immune system detects and clears virus Experienced durable HBsAg loss up to 2 years after stopping treatment Inarigivir monotherapy ant

  16. Slide 16: "Suppress & Shock" Adding Inarigivir in Virally Suppressed Patients

    14 • SPRING BANK PHARMACEUTICALS, INC. © 2018 “SHOCK” inarigivir once daily for 12-24 weeks Durable HBsAg loss “SUPPRESS & SHOCK” ADDING INARIGIVIR IN VIRALLY SUPPRESSED PATIENTS Host immune system activated and clears virus Inarigivir immunomodulation anticipated to be studied in a Phase 2b/3 trial

  17. Slide 17: SB 9225 – Fixed-Dose Combination for Naïve HBV

    SB 9225 (inarigivir + TDF) Ph 2b/3 program in US, EU and ASIA (anticipated Q3 2019) Newly diagnosed chronic HBV patients SB 9225 once-daily vs. TDF alone 24 week duration of treatment Primary endpoints: HBV DNA & durable HBsAg loss SB 9225 + siRNA / other MOA – addressing HBsAg high viral burden pop

  18. Slide 18: Clinical development timeline 2018-2020

    16 • SPRING BANK PHARMACEUTICALS, INC. © 2018 Q1 Q2 Q3 Q1 Q2 Q3 2019 2018 2020 Ph 2 ACHIEVE final cohort: 200 mg monotherapy arm “Stop & Shock” inarigivir monotherapy Ph 2b/3 in low viral burden patients “Suppress & Shock” inarigivir monotherapy Ph 2b/3 in virally suppressed patients Ph 2 Gilead stu

  19. Slide 19: Inarigivir ACHIEVE Trial Results and HBV Clinical Program Update

    17 • SPRING BANK PHARMACEUTICALS INC. © 2018 Patient convenience and safety are critical to success in HBV Inarigivir is a once daily oral therapy with a demonstrated favorable safety profile in the clinic Dose dependent responses in Cohort 3 in the ongoing ACHIEVE Trial Maximum reduction in HBV DNA

Spring Bank Pharmaceuticals — Corporate Update (August 2018) on 6ix